In accordance with this finding, in this study, osimertinib failed to suppress p-STAT3 in H1975 cells (Fig. 4B), and we demonstrated that combined treatment with osimertinib and YHO-1701 induced synergistic tumor growth inhibition (Figs. 2 and 4A). This evidence concerns the gene STAT3 and neoplasm.